Please login to the form below

Not currently logged in
Email:
Password:

Hydra Biosciences and Pfizer sign global R&D novel ion-channel agreement

Hydra Biosciences signs a collaboration agreement with Pfizer Global R&D to develop TRPV3-antagonist products for pain

Hydra Biosciences has signed a collaboration agreement with Pfizer Global R&D to develop TRPV3-antagonist product candidates for pain.

Per the agreement, US-based Hydra will receive upfront and success-based development milestone payments of USD 195m for the first developed product launched and more for additional approved indications.

Pfizer will fund all R&D under the agreement and will receive exclusive access to Hydra's current TRPV3 patents as well as an exclusive license to commercialise any compound from the collaboration. Once the products are on the market, Pfizer will pay worldwide royalties to Hydra.

Recent research on Transient Receptor Potential (TRP) antagonists indicates that they may act as multimodal signal integrators. Since TRP channels are only distantly related to voltage gated channels and homology among TRP family members is quite low, it is anticipated that specific and selective modulators may be more readily identified in this family than in other ion channel groups, limiting the potential for off-target effects, which have proven problematic in other ion channel families, such as Vioxx (rofecoxib) and other COX-2 inhibitors.

30th July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics